• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    10/11/23 1:31:05 PM ET
    $AKRO
    $BXRX
    $CELU
    $DVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Misc Health and Biotechnology Services
    Health Care
    Get the next $AKRO alert in real time by email

    Gainers

    • Tempest Therapeutics (NASDAQ:TPST) stock rose 1642.4% to $4.18 during Wednesday's regular session. The current volume of 141.8 million shares is 24870.9% of Tempest Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $55.6 million.
    • Phio Pharma (NASDAQ:PHIO) shares increased by 55.74% to $2.16. Trading volume for Phio Pharma's stock is 41.3 million as of 13:30 EST. This is 165963.8% of its average full-day volume over the last 100 days. The company's market cap stands at $4.8 million.
    • PaxMedica (NASDAQ:PXMD) shares increased by 32.71% to $0.29. As of 13:30 EST, this security is trading at a volume of 3.5 million shares, making up 450.2% of its average full-day volume over the last 100 days. The company's market cap stands at $4.9 million.
    • Baudax Bio (NASDAQ:BXRX) shares rose 30.15% to $0.34. As of 13:30 EST, this security is trading at a volume of 3.0 million shares, making up 105.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.1 million.
    • Celularity (NASDAQ:CELU) stock moved upwards by 28.78% to $0.26. The current volume of 2.0 million shares is 383.7% of Celularity's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $48.6 million.
    • Sharecare (NASDAQ:SHCR) stock increased by 25.08% to $1.17. Trading volume for Sharecare's stock is 2.6 million as of 13:30 EST. This is 141.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $417.8 million.

    Losers

    • Silk Road Medical (NASDAQ:SILK) stock decreased by 50.1% to $6.99 during Wednesday's regular session. As of 13:30 EST, Silk Road Medical's stock is trading at a volume of 14.9 million, which is 1664.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $271.2 million.
    • Outset Medical (NASDAQ:OM) shares decreased by 22.19% to $7.54. The current volume of 2.5 million shares is 422.7% of Outset Medical's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $375.4 million.
    • Akero Therapeutics (NASDAQ:AKRO) stock fell 21.05% to $14.33. The current volume of 6.6 million shares is 551.1% of Akero Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $796.7 million.
    • DaVita (NYSE:DVA) shares decreased by 18.66% to $74.25. As of 13:30 EST, DaVita's stock is trading at a volume of 6.1 million, which is 859.1% of its average full-day volume over the last 100 days. The company's market cap stands at $6.7 billion.
    • Fresenius Medical Care (NYSE:FMS) shares declined by 18.51% to $17.07. As of 13:30 EST, Fresenius Medical Care's stock is trading at a volume of 2.8 million, which is 692.2% of its average full-day volume over the last 100 days. The company's market cap stands at $10.0 billion.
    • ProKidney (NASDAQ:PROK) stock declined by 16.19% to $3.78. The current volume of 492.6K shares is 126.0% of ProKidney's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $232.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AKRO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKRO
    $BXRX
    $CELU
    $DVA

    CompanyDatePrice TargetRatingAnalyst
    Tempest Therapeutics Inc.
    $TPST
    1/22/2026$11.00Neutral → Buy
    H.C. Wainwright
    Fresenius Medical Care AG
    $FMS
    1/20/2026Buy → Neutral
    Goldman
    ProKidney Corp.
    $PROK
    12/16/2025$12.00Buy
    H.C. Wainwright
    Fresenius Medical Care AG
    $FMS
    10/15/2025Neutral → Underperform
    BofA Securities
    Akero Therapeutics Inc.
    $AKRO
    9/4/2025$72.00Buy
    H.C. Wainwright
    Fresenius Medical Care AG
    $FMS
    9/2/2025Neutral → Sell
    UBS
    Akero Therapeutics Inc.
    $AKRO
    8/4/2025$76.00Buy
    TD Cowen
    ProKidney Corp.
    $PROK
    6/30/2025$1.00Neutral → Underperform
    BofA Securities
    More analyst ratings

    $AKRO
    $BXRX
    $CELU
    $DVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Tempest Therapeutics upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Tempest Therapeutics from Neutral to Buy and set a new price target of $11.00

    1/22/26 8:24:05 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fresenius Medical downgraded by Goldman

    Goldman downgraded Fresenius Medical from Buy to Neutral

    1/20/26 9:08:47 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    H.C. Wainwright initiated coverage on ProKidney Corp. with a new price target

    H.C. Wainwright initiated coverage of ProKidney Corp. with a rating of Buy and set a new price target of $12.00

    12/16/25 9:01:44 AM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AKRO
    $BXRX
    $CELU
    $DVA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, Pres. & CEO Bitterman Robert J bought $5,150 worth of shares (5,000 units at $1.03), increasing direct ownership by 2% to 291,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    1/2/26 4:05:06 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, Pres. & CEO Bitterman Robert J bought $5,100 worth of shares (5,000 units at $1.02), increasing direct ownership by 2% to 286,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    12/29/25 8:10:21 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, Pres. & CEO Bitterman Robert J bought $5,700 worth of shares (5,000 units at $1.14), increasing direct ownership by 2% to 281,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    11/24/25 12:54:10 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKRO
    $BXRX
    $CELU
    $DVA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Outset Medical Inc.

    SCHEDULE 13G/A - Outset Medical, Inc. (0001484612) (Subject)

    3/27/26 11:19:26 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by DaVita Inc.

    SCHEDULE 13G/A - DAVITA INC. (0000927066) (Subject)

    3/26/26 5:39:34 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    Tempest Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

    8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)

    3/23/26 8:17:19 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKRO
    $BXRX
    $CELU
    $DVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

    WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced the appointment of Greg Madison as Chief Commercial Officer. In this role, Mr. Madison will drive ProKidney's commercial strategy as the Company advances towards the potential commercialization of rilparencel. "Greg is a seasoned commercial biopharma executive with a proven track record of building high-performing organizations, shaping strategy, and preparing innovative therapies for market," said Bruce Culleton, M.D., CEO of ProKidney. "He brings valuable operation

    3/25/26 4:01:00 PM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tempest Therapeutics Announces Up To $6 Million Private Placement

    BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) (the "Company"), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 925,927 shares of common stock (or pre-funded warrant in lieu thereof), series A warrants to purchase up to 925,927 shares of common stock and short-term series B warrants to purchase up to 925,927 shares of common stock, at a combined purchase price of $2.16 per share of common stock (or $2.159 per pre-funded warrant in lieu thereof) and accompanyi

    3/23/26 8:00:00 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement

    Prestigious Late-Breaking Research Session Positions PH-762 as a Promising New PD-1 Directed Immunotherapy Candidate on March 28, 2026 at 3 PM (MDT)King of Prussia, Pennsylvania--(Newsfile Corp. - March 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that a podium presentation addressing its lead product candidate, PH-762, will be given in the American Academy of Dermatology's Late-Breaking Research Session S034 on March 28, 2026 in Denver, Colorado. The presentation, entitled "PD-1 Directed Intratumoral Immunother

    3/23/26 7:00:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKRO
    $BXRX
    $CELU
    $DVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Angel Matthew

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    3/25/26 5:32:36 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by Fresenius Medical Care AG

    3 - Fresenius Medical Care AG (0001333141) (Issuer)

    3/18/26 10:01:24 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Director Arway Pamela M was granted 332 shares, increasing direct ownership by 1% to 26,695 units (SEC Form 4)

    4 - DAVITA INC. (0000927066) (Issuer)

    3/17/26 4:10:27 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $AKRO
    $BXRX
    $CELU
    $DVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PaxMedica Inc.

    SC 13G/A - PaxMedica, Inc. (0001811623) (Subject)

    11/14/24 7:22:38 PM ET
    $PXMD
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Fresenius Medical Care AG

    SC 13G - Fresenius Medical Care AG (0001333141) (Subject)

    11/14/24 4:08:53 PM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Akero Therapeutics Inc.

    SC 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)

    11/14/24 3:59:41 PM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKRO
    $BXRX
    $CELU
    $DVA
    Financials

    Live finance-specific insights

    View All

    Fresenius Medical Care delivers 27% earnings growth in 2025 and reaches upper end of its financial outlook; margin within 2025 mid-term target band

    Strong organic revenue growth1 in 2025 of 8% driven by all operating segmentsDriven by an exceptional Q4, full year operating income2 growth of 27% reached top end of financial outlook, resulting in a significant margin step up to 11.3%Reported operating income grew by 31%, reported net income3 by 82%Earnings per share2 (EPS) grew by 44%, supported by the accelerated share buyback programDividend of EUR 1.49 (+3%) planned to be proposedFY 2026 outlook operating income is forecast to remain on a consistent level despite significant additional headwindsBAD HOMBURG, Germany, Feb. 24, 2026 /PRNewswire/ -- "Fresenius Medical Care closed a milestone year marked by outstanding profitability gains.

    2/24/26 7:00:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. 4th Quarter 2025 Results

    DENVER, Feb. 2, 2026 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter and year ended December 31, 2025. "Our strong platform delivered once again in 2025, providing high quality, innovative care to our patients and achieving the financial targets we set out at the beginning of the year despite a challenging environment," said Javier Rodriguez, CEO of DaVita. "Given our ongoing investments and process improvements, we are confident in our ability to continue to deliver both clinically and financially in 2026 and beyond." Financial and operating highlights for the quarter and year ended December 31, 2025: Consolidated revenues were $3.620 billion

    2/2/26 4:05:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    Outset Medical to Report Fourth Quarter 2025 Financial Results on Wednesday, February 11, 2026

    SAN JOSE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the fourth quarter and full-year 2025 after the close of trading on Wednesday, February 11, 2026. On the same day, at 1:30 p.m. Pacific time (4:30 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Renee Gaeta, Chief Financial Officer, will host a conference call to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 1:30 p.m. Pacific time (4:30 p.m. E

    1/26/26 4:05:00 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AKRO
    $BXRX
    $CELU
    $DVA
    Leadership Updates

    Live Leadership Updates

    View All

    ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

    WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced the appointment of Greg Madison as Chief Commercial Officer. In this role, Mr. Madison will drive ProKidney's commercial strategy as the Company advances towards the potential commercialization of rilparencel. "Greg is a seasoned commercial biopharma executive with a proven track record of building high-performing organizations, shaping strategy, and preparing innovative therapies for market," said Bruce Culleton, M.D., CEO of ProKidney. "He brings valuable operation

    3/25/26 4:01:00 PM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products

    Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified suite of 6 established regenerative biomaterial products, most with existing insurance reimbursement, along with three new product 510(k) filings planned for 2026, 2027, and 2028 Experienced commercial team is expected to join NEXGEL, significantly expanding the Company's sales reach and operational capabilities LANGHORNE, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) pr

    3/10/26 8:45:00 AM ET
    $CELU
    $NXGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference

    Phio's Presentation to take place on Wednesday January 28, 2026 at 9 AM ETKing of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026 at the Borgata Hotel in Atlantic City, NJ.Robert Bitterman, CEO and Chairman of the Board of Phio Pharmaceuticals will deliver a company presentation on January 28th at 9 AM in Borgata Hotel Room #1 and the management team will be avai

    1/26/26 8:15:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care